(3-BENZYL-3-METHYL-2,3-DIHYDROBENZOFURAN-6- YL)(PIPERIDIN-1-YL)METHANONE for Mild cognitive impairment | Alzheimer's disease (mild to moderate)

Inclusion criteria

• {"criterion_text":"- Participants must be 65-80 years of age inclusive, at the time of signing the informed consent.\n- Body weight within 55-110 kg and body mass index (BMI) within the range 18-35 kg/m2 (inclusive)\n- Male participants: Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days, after the last dose of study intervention: Refrain from donating sperm PLUS, either: - Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent. OR - Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential who is not currently pregnant. - Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person. a. Female participants: - Must be a woman of nonchildbearing potential (WONCBP) (at least two years post-menopause or surgically sterile).\n- Clinical Dementia Rating (CDR) of 0.5 - 2.0; MMSE 12-26\n- pTau 217 consistent with AD, or recent amyloid test panel within 2 years. The test must be after any previous participation in an anti-amyloid MAB trial.\n- Participants who have been in a previous amyloid-directed MAB study must have a negative ARIA report after the study.\n- Confirmed medical documentation of AD symptoms onset at age 60 or later.\n- No active depression and a Geriatric Depression Score of < 6.\n- No change in acetylcholinesterase inhibitors or memantine for the previous six months and is not expected to start an acetylcholinesterase inhibitor during the duration of the study.\n- Living at home, with a reliable caregiver who sees them at least 3 times/week for 10 hours or more and can oversee the administration of the study drug.\n- Provide written informed consent and willingness as documented by a signed in-formed consent form; responsible caregiver must also provide written consent."}

Exclusion criteria

• {"criterion_text":"- Reported history or presence of clinically significant history of or cur-rent cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data. Participants with stable, well-controlled conditions may be accepted upon review by the investigator and sponsor.\n- Findings on MRI demonstrating intracranial pathology as an alternative cause for cognitive impairment.\n- Any other reported history of central nervous system (CNS) trauma (e.g., contusion), or infections (e.g., human immunodeficiency virus [HIV], syphilis), that present active or residual effects on cognitive function.\n- Reported past or intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing. Specific medications listed in Section 9.9 concomitant therapy may be allowed.\n- Reported hepatic or biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones) that are deemed clinically significant by the PI or medical monitor.\n- Autoimmune disorders, active infections or other disorders, including the use of immunosuppressants, that may affect the subject’s immune system.\n- Reported current or chronic history of clinically significant liver disease. This includes but is not limited to hepatitis virus infections, drug- or alcohol-related liver disease, nonalcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson’s disease, α-1 antitryp-sin deficiency, primary biliary cholangitis, primary sclerosing cholangitis, or any other liver disease considered clinically significant by the investigator.\n- Abnormal TSH, fT3 or fT4 at baseline screening. Subjects with known hypothyroidism or hyperthyroidism should be stable on treat-ment for 6 months prior to starting study and not anticipated to require any type of dose adjustment during the course of the study.\n- Reside in a nursing home or assisted care facility with the need for direct continuous medical care and nursing supervision. Participant may reside in such facilities provided continuous direct medical care is not required.\n- Subjects who require close or continual monitoring for self care or basic activities of daily living.\n- Subjects with history of psychiatric conditions such as schizophrenia and or bipolar disorder\n- Presence of any contraindication to venous blood sampling for pharmacokinetic analyses.\n- Any reported history from the patient, family, or on supplied chart review or current suicide risk\n- Reported treatment with biological agents in the 3 months prior to dosing in this study, or within 5 half-lives of the biological agent prior to dosing.\n- Change of more than 2 points from screening MMSE to baseline MMSE, or discrepancy in disease classification between MMSE, and Trail Making test.\n- Current enrollment or past participation within the last 30 days before signing of consent in any other clinical study involving an investigational study intervention.\n- Vaccination: Subjects should avoid receiving any vaccinations during the 28-day study period to minimize potential confounding effects from post-vaccination immune responses. Subjects must receive vac-cinations at least one month prior to the screening visit to ensure there is no acute-phase reaction that could impact study results.\n- Reported history of seizures, with the exception of childhood febrile seizures or metabolic seizures where the underlying etiology has resolved, and the participant has been seizure-free without treatment for at least 2 years.\n- Positive SARS-CoV-2 test, hepatitis panel (including hepatitis B surface antigen [HBsAg] or hepatitis C virus antibody [anti-HCV]), a positive HIV antibody screen or positive syphilis test.\n- Diagnosis of a dementia-related CNS disease other than AD (eg, Parkinson’s Disease, Huntington’s Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus)\n- Cannot tolerate spinal puncture procedure for cerebral spinal fluid (CSF).\n- Anticoagulation therapy that would contraindicate spinal puncture procedure for cerebral spinal fluid (CSF). Subjects on anti-coagulation therapy undergoing lumbar punctures: Subjects requiring ongoing anti-coagulation therapy should only be considered for screening and enrollment if the Principal Investigator (PI) determines it is safe to temporarily withhold anti-coagulation treatment in order to perform lumbar punctures. Before enrolling a subject on anti-coagulation therapy, the PI must confirm and docu-ment that withholding anti-coagulation for the lumbar puncture pro-cedure does not pose an undue risk to the subject.\n- Any contraindication to MRI (per facility standard of care).\n- Major structural brain disease by reported history or chart review (e.g., ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions, severe micro-angiopathic disease, volume loss disproportionate for age or a single lesion in a critical region e.g., thalamus, hippocampus)."}

Primary endpoints

• {"endpoint_text":"- To determine the safety and tolerability in AD subjects following 28 days of administration of NTRX-07","definition_or_measurement_approach":"Safety and tolerability as assessed by the number of adverse events of NTRX-07 administered for 28 days (as stated in trial main objective)."}

Secondary endpoints

• {"endpoint_text":"- Plasma and CSF pharmacokinetics of NTRX-07","definition_or_measurement_approach":"Measurement of plasma and cerebrospinal fluid concentrations to characterise pharmacokinetic properties of NTRX-07 following 28 days of administration."}

Poland

Earliest CTIS Part Ii Submission Date

20-01-2025

Latest Decision Or Authorization Date

07-07-2025

Processing Time Days

168

Number Of Sites

3

Number Of Participants

16

Hungary

Earliest CTIS Part Ii Submission Date

22-12-2024

Latest Decision Or Authorization Date

03-07-2025

Processing Time Days

193

Number Of Sites

2

Number Of Participants

16

Czechia

Earliest CTIS Part Ii Submission Date

07-01-2025

Latest Decision Or Authorization Date

04-08-2025

Processing Time Days

209

Number Of Sites

2

Number Of Participants

16

Primary sponsor

Full Name

Neurotherapia Inc.

Organisation Type

Pharmaceutical company

Country Of Registered Address

United States

Contract research organisations

Name

Cruint Global Consulting Pte Ltd

Responsibilities

Sponsor/operational duties indicated (sponsorDuties codes: 1,12,2,5); contact pkovacs@cruint.com; phone +6588918322

Third parties

• {"country":"Singapore","full_name":"Cruint Global Consulting Pte Ltd","duties_or_roles":"sponsorDuties codes: 1, 12, 2, 5; contact pkovacs@cruint.com; phone +6588918322","organisation_type":"Pharmaceutical company"}
• {"country":"Hungary","full_name":"Pharma-Regist Kft.","duties_or_roles":"sponsorDuties code: 8; contact info@pharmaregist.hu; phone +3613187160","organisation_type":"Pharmaceutical company"}
• {"country":"France","full_name":"Firalis","duties_or_roles":"Biomarker analysis (sponsorDuties code 15 and code 4); contact sales@firalis.com; phone +33389911320","organisation_type":"Pharmaceutical company"}